OP0053 Eular/ERA-EDTA Recommendations for The Management of Anca-Associated Vasculitis

OP0053 Eular/ERA-EDTA Recommendations for The Management of Anca-Associated Vasculitis

Detalhes bibliográficos
Main Authors:	Yates, M, Watts, R, Bajema, I, Cid, M, Crestani, B, Hauser, T, Hellmich, B, Holle, J, Laudien, M, Little, M, Luqmani, R, Mahr, A, Merkel, P, Mills, J, Mooney, J, Segelmark, M, Tesar, V, Westman, K, Vaglio, A, Yalçındağ, N, Jayne, D, Mukhtyar, C
Formato:	Conference item
Publicado em:	BMJ Publishing Group 2016

Registos relacionados

EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis
Por: Yates, M, et al.
Publicado em: (2016)

EULAR/ERA-EDTA RECOMMENDATIONS FOR THE MANAGEMENT OF ANCA-ASSOCIATED VASCULITIS
Por: Yates, M, et al.
Publicado em: (2016)

Validation of the EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis by disease content experts
Por: Yates, M, et al.
Publicado em: (2017)

EULAR recommendations for conducting clinical studies and/or clinical trials in ANCA-associated vasculitis
Por: Luqmani, R, et al.
Publicado em: (2007)

SP0053 Hot session: vasculitis treatment
Por: Luqmani, R
Publicado em: (2017)

Eular recommendations for vasculitis
Por: Luqmani, R, et al.
Publicado em: (2007)

THE 2016 EUROPEAN (EULAR/ERA-EDTA) RECOMMENDATIONS FOR THE DIAGNOSIS AND MANAGEMENT OF ANCA-ASSOCIATED SYSTEMIC VASCULITIS
Por: T. V. Beketova
Publicado em: (2017-03-01)

EULAR recommendations for the management of large vessel vasculitis.
Por: Mukhtyar, C, et al.
Publicado em: (2009)

Cardiovascular outcomes in ANCA associated vasculitis
Por: Mukhtyar, C, et al.
Publicado em: (2008)

Rituximab versus cyclophosphamide in ANCA-associated renal vasculitis.
Por: Jones, R, et al.
Publicado em: (2010)

EULAR recommendations for the management of primary small and medium vessel vasculitis.
Por: Mukhtyar, C, et al.
Publicado em: (2009)

Current evidence of factors influencing remission, relapse, renal failure and mortality in patients with systemic vasculitis. A systematic review for the EULAR systemic vasculitis task force
Por: Mukhtyar, C, et al.
Publicado em: (2007)

Randomized trial of rituximab vs cyclophosphamide for ANCA-associated renal vasculitis: RITUXVAS
Por: Jones, R, et al.
Publicado em: (2009)

Comparison of disease activity measures for ANCA-associated vasculitis.
Por: Merkel, P, et al.
Publicado em: (2004)

Long-term survival of ANCA-associated vasculitis
Por: Flossmann, O, et al.
Publicado em: (2009)

Eular recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis
Por: Hellmich, B, et al.
Publicado em: (2006)

Diagnosis and management of ANCA associated vasculitis.
Por: Berden, A, et al.
Publicado em: (2012)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): part 1—treatment of granulomatosis with polyangiitis and microscopic polyangiitis
Por: Sara Monti, et al.
Publicado em: (2023-07-01)

Long-term patient survival in ANCA-associated vasculitis
Por: Flossmann, O, et al.
Publicado em: (2011)

Long-term patient survival in ANCA-associated vasculitis.
Por: Flossmann, O, et al.
Publicado em: (2011)

Comparison of disease activity measures for anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis.
Por: Merkel, P, et al.
Publicado em: (2009)

New ACR/EULAR 2022 classification criteria for ANCA-associated vasculitis
Por: T. V. Beketova
Publicado em: (2023-10-01)

Long-term patient survival in ANCA-associated vasculitis.
Por: Flossmann, O, et al.
Publicado em: (2011)

Systematic literature review informing the 2022 update of the EULAR recommendations for the management of ANCA-associated vasculitis (AAV): Part 2 - Treatment of eosinophilic granulomatosis with polyangiitis and diagnosis and general management of AAV
Por: Sara Monti, et al.
Publicado em: (2023-06-01)

THE DEMOGRAPHY OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
Por: Yew, S, et al.
Publicado em: (2012)

EULAR recommendations for conducting clinical studies and/or clinical trials in systemic vasculitis: focus on anti-neutrophil cytoplasm antibody-associated vasculitis.
Por: Hellmich, B, et al.
Publicado em: (2007)

EULAR points to consider in the development of classification and diagnostic criteria in systemic vasculitis.
Por: Basu, N, et al.
Publicado em: (2010)

THE DISEASE CHARACTERISTICS OF ANCA ASSOCIATED VASCULITIS: 735 PATIENTS RECRUITED AT DIAGNOSIS TO SIX EUROPEAN VASCULITIS STUDY GROUP TRIALS
Por: Yew, S, et al.
Publicado em: (2012)

TREATMENT-RELATED DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
Por: Robson, J, et al.
Publicado em: (2013)

The prognostic value of BVAS and VDI in ANCA-AAV
Por: Suppiah, R, et al.
Publicado em: (2011)

The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part I
Por: N. L. Kozlovskaya, et al.
Publicado em: (2020-11-01)

The 2019 updated EULAR/ERA-EDTA guidelines for the management of lupus nephritis. Expert comments. Part II
Por: N. L. Kozlovskaya, et al.
Publicado em: (2021-02-01)

THE PROGNOSTIC VALUE OF THE BIRMINGHAM VASCULITIS ACTIVITY SCORE AND THE VASCULITIS DAMAGE INDEX IN ANCA-ASSOCIATED VASCULITIS
Por: Suppiah, R, et al.
Publicado em: (2011)

Reseña a Enseñar África. doi 10.20420/GUIN.2013.0053
Por: Marino Alduán Guerra
Publicado em: (2014-07-01)

Podocytes and Proteinuria in ANCA-Associated Glomerulonephritis: A Case-Control Study
Por: Emma E. van Daalen, et al.
Publicado em: (2019-06-01)

Nomenclature and classification of vasculitis - update on the ACR/EULAR diagnosis and classification of vasculitis study (DCVAS).
Por: Luqmani, R, et al.
Publicado em: (2011)

Damage in the anca-associated vasculitides: long-term data from the European Vasculitis Study group (EUVAS) therapeutic trials.
Por: Robson, J, et al.
Publicado em: (2015)

Damage in the ANCA-associated vasculitides: Long-term data from the European Vasculitis Study Group (EUVAS) therapeutic trials
Por: Robson, J, et al.
Publicado em: (2015)

FACTORS ASSOCIATED WITH LONG-TERM DAMAGE IN THE ANCA-ASSOCIATED VASCULITIDES: AN ANALYSIS OF COHORTS FROM THE EUROPEAN VASCULITIS STUDY GROUP THERAPEUTIC TRIALS
Por: Robson, J, et al.
Publicado em: (2013)

Cutaneous manifestations of ANCA-associated vasculitis
Por: Chiesafuxench, Z, et al.
Publicado em: (2016)